

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Currently amended) A pharmaceutical composition comprising a GLP-1 agonist and a gastrin compound that provides beneficial effects relative to each compound alone, and optionally a pharmaceutically acceptable carrier, excipient, or vehicle.

Claims 2-5 (Cancelled)

6. (Original) A pharmaceutical composition as claimed in claim 1 wherein the ratio of a GLP-1 agonist to a gastrin compound is from about 1:1 to 1:110, 1:1 to 1:100, 1:1 to 1:75, 1:1 to 1:50, 1:1 to 1:25, 1:1 to 1:10, 1:1 to 1:5, and 1:1.

Claims 7-8 (Cancelled)

9. (Currently amended) A pharmaceutical composition as claimed in ~~any preceding~~ claim 1 wherein the GLP-1 agonist and the gastrin compound are present in doses that are at least about 1.1 to 1.4, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, or 10 fold lower than the doses of each compound alone required to treat a condition and/or disease.

10. (Original) A pharmaceutical composition as claimed in claim 1 comprising an additive amount of the GLP-1 agonist and the gastrin compound in a pharmaceutically acceptable excipient, carrier, or vehicle.

11. (Original) A pharmaceutical composition as claimed in claim 1 comprising a synergistically effective amount of the GLP-1 agonist and the gastrin compound in a pharmaceutically acceptable excipient, carrier, or vehicle.

12. (Original) A pharmaceutical composition as claimed in claim 1 comprising between 0.1 to 20, 0.1 to 30, 0.1 to 40, 0.1 to 50, and 0.1 to 60 micrograms/kg/day GLP-1 agonist and 0.1 to 20, 0.1 to 30, 0.1 to 40, 0.1 to 50, and 0.1 to 60 micrograms/kg/day gastrin compound.

Claims 13-18 (Cancelled)

19. (Currently amended) A pharmaceutical composition as claimed in ~~any preceding~~ claim 1 wherein the beneficial effect is a decrease in blood glucose levels for a period of at least 2, 4, 6, 8, or 10 weeks, 2 to 4 weeks, 2 to 6 weeks, 2 to 8 weeks, 2 to 12 weeks, 2 to 24 weeks, 2 weeks to 12 months, and 2 weeks to 18 months following treatment.

20. (Currently amended) A pharmaceutical composition as claimed in ~~any preceding~~ claim 1 wherein the GLP-1 agonist is a GLP-1(1-37), GLP-1(7-36) amide, fragments, analogues, and derivatives thereof, and active metabolites and prodrugs of GLP-1.

Claims 21-23 (Cancelled)

24. (Currently amended) A pharmaceutical composition as claimed in ~~any preceding~~ claim 1 wherein the gastrin compound is gastrin 71 [SEQ ID NO. 15], gastrin 52 [SEQ ID NO. 16], gastrin 34 (big gastrin) [SEQ ID NO. 11 or 12], gastrin 17 (little gastrin) [SEQ ID NO. 13 or 14], gastrin 14 [SEQ ID NO. 17], gastrin 8, gastrin 6 [SEQ ID NO. 18 or 19], pentagastrin, and tetragastrin, or a fragment, analog, or derivative thereof.

Claims 25-26 (Cancelled)

27. (Currently amended) A pharmaceutical composition of ~~any preceding~~ claim 1 wherein the GLP-1 agonist is Arg34Lys26(Ne(g-Glu(Na-hexadecanoyl)))-GLP-1(7-37) and the gastrin compound is 15Leu gastrin 17 [SEQ ID NO. 14].

Claim 28 (Cancelled)

29. (Currently amended) A method for preparing a stable pharmaceutical composition of a GLP-1 agonist comprising mixing a GLP-1 agonist, a gastrin compound, and a pharmaceutically

acceptable carrier, excipient, or vehicle effective to physically stabilize the GLP-1 agonist and adapted to provide beneficial effects, ~~preferably sustained beneficial effects.~~

Claims 30-33 (Cancelled)

34. (Currently amended) A method of treatment comprising administering to a subject a therapeutically effective amount of a composition according to claim 1 or at least one GLP-1 agonist in combination with administration of at least one gastrin compound which upon administration to a subject with symptoms of diabetes provides sustained beneficial effects.

Claim 35 (Cancelled)

36. (Currently amended) A method as claimed in claim 34 ~~or 35~~ wherein therapeutically effective amounts of the GLP-1 agonist and the gastrin compound are combined prior to administration to the subject.

37. (Currently amended) A method as claimed in claim 34 ~~or 35~~ wherein therapeutically effective amounts of the GLP-1 agonist and the gastrin compound are administered to the subject sequentially.

Claims 38-39 (Cancelled)

40. (Currently amended) A method of treating ~~a condition and/or disease~~ diabetes comprising administering a ~~GLP-1 agonist and a gastrin compound, or a composition or conjugate of any preceding claim 1~~ with a plurality of cells to a subject in need thereof to thereby produce beneficial effects, ~~preferably sustained beneficial effects.~~

Claims 41-51 (Cancelled)

52. (New) A pharmaceutical composition according to claim 24 wherein the GLP-1 agonist is an exendin or analog, derivative or fragment thereof.

53. (New) A method according to claim 34 wherein the GLP-1 agonist is an exendin or analog, derivative or fragment thereof.

54. (New) A method according to claim 54 wherein the GLP-1 agonist is exendin-3 or exendin-4.

55. (New) A method according to claim 54 wherein the GLP-1 agonist is exenatide.